Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder

Neuropsychopharmacology

Volumn 39, Issue 6, 2014, Pages 1388-1398

  Madhoo, Manisha ^a   Keefe, Richard S E ^b   Roth, Robert M ^c   Sambunaris, Angelo ^d   Wu, James ^a   Trivedi, Madhukar H ^e   Anderson, Colleen S ^a   Lasser, Robert ^f  

^a SHIRE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d Atlanta Medical Research Institute   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

augmentation; clinical drug studies; executive function; lisdexamfetamine dimesylate; major depressive disorder

Indexed keywords

LISDEXAMFETAMINE; PLACEBO; ANTIDEPRESSANT AGENT; DEXAMPHETAMINE; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; BEHAVIOR RATING INVENTORY OF EXECUTIVE FUNCTION ADULT; COGNITIVE DEFECT; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; FATIGUE; FEMALE; GLOBAL EXECUTIVE COMPOSITE T SCORE; HUMAN; HYPERHIDROSIS; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PERSISTENT EXECUTIVE DYSFUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; REMISSION; RHABDOMYOLYSIS; SALMONELLOSIS; SELF REPORT; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SUICIDAL IDEATION; SYMPTOMATOLOGY; UNCONSCIOUSNESS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL GASTROENTERITIS; XEROSTOMIA; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATION; DRUG EFFECTS; EXECUTIVE FUNCTION; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; REMISSION INDUCTION; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84900798015     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.334     Document Type: Article

References (49)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. American Psychiatric Association: Washington, DC.
2. Arnsten AF (2006). Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 31: 2376-2383. (Pubitemid 44607054)
3. Arnsten AF, Li BM (2005). Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 57: 1377-1384. (Pubitemid 40798558)
4. Brooks BL, Sherman EM (2012). Computerized neuropsychological testing to rapidly evaluate cognition in pediatric patients with neurologic disorders. J Child Neurol 27: 982-991.
5. Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F (2009). Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One 4: e4824.
6. Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV (2009). Sheehan Suicidality Tracking Scale (Sheehan-STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry (Edgmont) 6: 26-31.
7. DeBattista C (2005). Executive dysfunction in major depressive disorder. Expert Rev Neurother 5: 79-83.
8. Elliott R (2003). Executive functions and their disorders. Br Med Bull 65: 49-59. (Pubitemid 36406457)
9. Endicott J, Nee J (1997). Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull 33: 13-16. (Pubitemid 27184189)
10. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29: 321-326. (Pubitemid 23311543)
11. Ferguson JM, Wesnes KA, Schwartz GE (2003). Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 18: 9-14. (Pubitemid 36127055)
12. Garlinghouse MA, Roth RM, Isquith PK, Flashman LA, Saykin AJ (2010). Subjective rating of working memory is associated with frontal lobe volume in schizophrenia. Schizophr Res 120: 71-75.
13. Grant MM, Thase ME, Sweeney JA (2001). Cognitive disturbance in outpatient depressed younger adults: evidence of modest impairment. Biol Psychiatry 50: 35-43. (Pubitemid 32701992)
14. Gualtieri CT, Johnson LG (2006). Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol 21: 623-643. (Pubitemid 44754740)
15. Gualtieri CT, Johnson LG, Benedict KB (2006). Neurocognition in depression: patients on and off medication versus healthy comparison subjects. J Neuropsychiatry Clin Neurosci 18: 217-225.
16. Guy W (1976). Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration; NIMH Psychopharmacology Research Branch: Rockville, MD, pp 218-222.
17. Harvey PD, Roth RM, Bilder RM, Richards C, Lasser R, Geibel B et al (2012). Assessment of executive dysfunction in adults with major depressive disorder receiving lisdexamfetamine dimesylate augmentation of escitalopram. 165th Annual Meeting of the American Psychiatric Association; May 5-9: Philadelphia, PA.
18. Herrera-Guzman I, Herrera-Abarca JE, Gudayol-Ferre E, Herrera-Guzman D, Gomez-Carbajal L, Pena-Olvira M et al (2010). Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res 177: 323-329.
19. Isquith PK, Roth RM, Gioia G (2013). Contribution of rating scales to the assessment of executive functions. Appl Neuropsychol Child 2: 125-132.
20. Iverson GL, Brooks BL, Langenecker SA, Young AH (2011). Identifying a cognitive impairment subgroup in adults with mood disorders. J Affect Disord 132: 360-367.
21. Iverson GL, Brooks BL, Young AH (2009). Identifying neurocognitive impairment in depression using computerized testing. Appl Neuropsychol 16: 254-261.
22. Keller A, McGarvey EL, Clayton AH (2006). Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther 32: 43-52.
23. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCSR). JAMA 289: 3095-3105. (Pubitemid 37432885)
24. Killgore WD, Muckle AE, Grugle NL, Killgore DB, Balkin TJ (2008). Sex differences in cognitive estimation during sleep deprivation: effects of stimulant countermeasures. Int J Neurosci 118: 1547-1557.
25. Kupfer DJ (2005). The pharmacological management of depression. Dialogues Clin Neurosci 7: 191-205. (Pubitemid 41284684)
26. Marazziti D, Consoli G, Picchetti M, Carlini M, Faravelli L (2010). Cognitive impairment in major depression. Eur J Pharmacol 626: 83-86.
27. McGregor C, Srisurapanont M, Mitchell A, Longo MC, Cahill S, White JM (2008). Psychometric evaluation of the Amphetamine Cessation Symptom Assessment. J Subst Abuse Treat 34: 443-449. (Pubitemid 351609289)
28. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE et al (2008). A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 63: 981-989.
29. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389. (Pubitemid 9136500)
30. Preiss M, Kucerova H, Lukavsky J, Stepankova H, Sos P, Kawaciukova R (2009). Cognitive deficits in the euthymic phase of unipolar depression. Psychiatry Res 169: 235-239.
31. Rabin LA, Fogel J, Nutter-Upham KE (2011). Academic procrastination in college students: the role of self-reported executive function. J Clin Exp Neuropsychol 33: 344-357.
32. Rabin LA, Roth RM, Isquith PK, Wishart HA, Nutter-Upham KE, Pare N et al (2006). Self- and informant reports of executive function on the BRIEF-A in MCI and older adults with cognitive complaints. Arch Clin Neuropsychol 21: 721-732. (Pubitemid 44635116)
33. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ et al (2007). Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164: 900-909. (Pubitemid 46972905)
34. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK (2007). A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68: 93-101. (Pubitemid 46220130)
35. Reppermund S, Ising M, Lucae S, Zihl J (2009). Cognitive impairment in unipolar depression is persistent and nonspecific: further evidence for the final common pathway disorder hypothesis. Psychol Med 39: 603-614.
36. Rogers MA, Kasai K, Koji M, Fukuda R, Iwanami A, Nakagome K et al (2004). Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res 50: 1-11. (Pubitemid 39024296)
37. Roth RM, Isquith PK, Gioia G (2013). The Behavior Rating Inventory of Executive Function (BRIEF) family of measures. In: Goldstein S, Naglieri J (eds). Executive Functioning Handbook. 2nd edn.
38. Roth RM, Isquith PK, Gioia GA (2005). Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Professional Manual. Psychological Assessment Resources: Lutz, FL.
39. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-1917. (Pubitemid 44807782)
40. Schachar R, Ickowicz A, Crosbie J, Donnelly GA, Reiz JL, Miceli PC et al (2008). Cognitive and behavioral effects of multilayerrelease methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 18: 11-24. (Pubitemid 351311242)
41. Snyder HR (2013). Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull 139: 81-132.
42. Spitzer RL, Kroenke K, Williams JB, Lowe B (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166: 1092-1097. (Pubitemid 43765180)
43. ten Doesschate MC, Koeter MW, Bockting CL, Schene AH (2010). Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord 120: 126-132.
44. Trivedi MH, Cutler A, Richards C, Lasser R, Geibel B, Gao J et al (2013). A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry 74: 802-809.
45. Vyvanse (lisdexamfetamine dimesylate) (2012). Full Prescribing Information. Shire US Inc: Wayne, PA.
46. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840-1847. (Pubitemid 34303629)
47. Ware J Jr., Kosinski M, Keller SD (1996). A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34: 220-233. (Pubitemid 126433231)
48. Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L (2009). Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 14: 573-585.
49. Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J (2010). Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct 6: 34.